These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Lower immunity to poliomyelitis viruses in Australian young adults not eligible for inactivated polio vaccine. Hendry AJ; Beard FH; Dey A; Quinn H; Hueston L; Dwyer DE; McIntyre PB Vaccine; 2020 Mar; 38(11):2572-2577. PubMed ID: 32037225 [TBL] [Abstract][Full Text] [Related]
4. A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people. Kim HJ; Hwang S; Lee S; Kwon Y; Park K; Park YJ; Bae GR; Lee SW; Jeong YS; Hyeon JY BMC Infect Dis; 2015 Mar; 15():164. PubMed ID: 25881203 [TBL] [Abstract][Full Text] [Related]
5. A study evaluating poliovirus antibodies and risk factors associated with polio seropositivity in low socioeconomic areas of Pakistan. Habib M; Soofi S; Ali N; Sutter RW; Palansch M; Qureshi H; Akhtar T; Molodecky NA; Okayasu H; Bhutta ZA Vaccine; 2013 Apr; 31(15):1987-93. PubMed ID: 23429005 [TBL] [Abstract][Full Text] [Related]
6. Poliovirus neutralizing antibody levels among individuals in three regions of Ghana. Opare JK; Akweongo P; Afari EA; Odoom JK Ghana Med J; 2019 Jun; 53(2):170-180. PubMed ID: 31481814 [TBL] [Abstract][Full Text] [Related]
7. Population immunity to polioviruses in the context of a large-scale wild poliovirus type 1 outbreak in Tajikistan, 2010. Khetsuriani N; Pallansch MA; Jabirov S; Saparova N; Oberste MS; Wannemuehler K; Ursu P; Wassilak S; Martin R Vaccine; 2013 Oct; 31(42):4911-6. PubMed ID: 23891502 [TBL] [Abstract][Full Text] [Related]
8. Poliomyelitis seroprevalence in high risk populations of India before the trivalent-bivalent oral poliovirus vaccine switch in 2016. Ahmad M; Verma H; Kunwar A; Soni S; Sinha U; Gawande M; Sethi R; Nalavade U; Sharma D; Bhatnagar P; Bahl S; Deshpande J Int J Infect Dis; 2021 Jan; 102():337-343. PubMed ID: 33130206 [TBL] [Abstract][Full Text] [Related]
9. Long-term persistence of poliovirus neutralizing antibodies in the era of polio elimination: An Italian retrospective cohort study. Bianchi FP; Larocca AMV; Bozzi A; Spinelli G; Germinario CA; Tafuri S; Stefanizzi P Vaccine; 2021 May; 39(22):2989-2994. PubMed ID: 33933314 [TBL] [Abstract][Full Text] [Related]
10. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. Duintjer Tebbens RJ; Hampton LM; Thompson KM BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of poliovirus vaccines in chronically malnourished infants: a randomized controlled trial in Pakistan. Saleem AF; Mach O; Quadri F; Khan A; Bhatti Z; Rehman NU; Zaidi S; Weldon WC; Oberste SM; Salama M; Sutter RW; Zaidi AK Vaccine; 2015 Jun; 33(24):2757-63. PubMed ID: 25917673 [TBL] [Abstract][Full Text] [Related]
12. Seroprevalence of poliovirus antibodies amongst children in Zaria, Northern Nigeria. Giwa FJ; Olayinka AT; Ogunshola FT Vaccine; 2012 Nov; 30(48):6759-65. PubMed ID: 23000220 [TBL] [Abstract][Full Text] [Related]